Roche
Executive Summary
To divest its human growth hormone releasing factor (GRF) business to Fujisawa Pharmaceutical pending Federal Trade Commission approval. FTC ordered Roche to divest its GRF business as a condition for approving the acquisition of Genentech, which markets Protropin human growth hormone. . . .